Chemotherapeutic composition using nanocrystalline calcium phosphate paste
First Claim
1. An anticancer composition comprising a mixture of an anticancer agent and a calcium phosphate paste, said paste comprised of one or more nanocrystalline or poorly crystalline calcium phosphates and a physiologically acceptable fluid, the paste having an injectable or formable consistency at the time of administration and hardenable at the tumor site.
2 Assignments
0 Petitions
Accused Products
Abstract
A method and composition are provided for treating cancer in a mammal. The method includes administering to a tumor site of the mammal an anticancer composition comprising a mixture of an anticancer agent and a nanocrystalline or poorly crystalline calcium phosphate paste, said paste comprised of one or more calcium phosphates and a physiologically acceptable fluid, the paste having an injectable or formable consistency at the time of administration and hardenable at the tumor
-
Citations
23 Claims
- 1. An anticancer composition comprising a mixture of an anticancer agent and a calcium phosphate paste, said paste comprised of one or more nanocrystalline or poorly crystalline calcium phosphates and a physiologically acceptable fluid, the paste having an injectable or formable consistency at the time of administration and hardenable at the tumor site.
- 18. An anticancer composition comprising cisplatin admixed with a calcium phosphate paste, said paste comprised of one or more nanocrystalline or poorly crystalline calcium phosphates and a physiologically acceptable fluid, the paste having an injectable or formable consistency at the time of administration and hardenable at the tumor site.
-
21. A kit for use in preparing a flowable anticancer composition that remains injectable for at least about 20 minutes, said kit comprising:
-
(a) dry ingredients comprising a nanocrystalline or poorly crystalline calcium phosphate and a second calcium phosphate in a proportion of about 1;
10 to 10;
1 by weight;
(b) a physiologically acceptable aqueous lubricant in an amount sufficient to produce a flowable product upon combination with said dry ingredients; and
(c) an anticancer agent in an amount ranging from about 0.01 to 10 wt. % of said dry ingredients. - View Dependent Claims (22, 23)
-
Specification